Enoxaparin

Evidence Level: L5

Predicted Indications: 1

Enoxaparin

Pharmacist Assessment Report

Enoxaparin: low-molecular-weight heparin (antithrombin-dependent factor Xa inhibitor) → thrombophilia due to protein C deficiency, autosomal recessive

One-Sentence Summary

Enoxaparin is a low-molecular-weight heparin anticoagulant marketed in Canada under several brand names. The TxGNN model predicts it may be effective for thrombophilia due to protein C deficiency, autosomal recessive, but the data compiled for this report contain no clinical trials and no publications for this specific condition, so the prediction rests on model output and mechanistic reasoning only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	thrombophilia due to protein C deficiency, autosomal recessive
TxGNN Prediction Score	0.9958
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the compiled record. Based on general pharmacology, enoxaparin potentiates antithrombin III and inhibits factor Xa, and to a lesser degree thrombin.

In autosomal recessive (severe or homozygous) protein C deficiency, the protein C anticoagulant pathway, which normally inactivates factors Va and VIIIa, is impaired. This leads to unchecked thrombin generation and thrombosis, including neonatal purpura fulminans. Because enoxaparin acts through an independent, antithrombin-dependent pathway, it could in principle compensate for the missing anticoagulant activity.

This link is biologically plausible, and the high TxGNN score (0.9958) likely reflects the closeness of related thrombotic conditions to this disease. However, it is a computational prediction supported by mechanistic reasoning, not direct clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

The local records list 20 valid single-ingredient licences (the list may be partial). Indication text, dosage form and manufacturer are not recorded for these licences. Main products:

DIN	Product Name	Dosage Form	Approved Indication
02509156	REDESCA HP	Not recorded	Not recorded
02506505	NOROMBY HP	Not recorded	Not recorded
02539985	AXBERI	Not recorded	Not recorded
02532298	ELONOX	Not recorded	Not recorded
02378469	LOVENOX HP	Not recorded	Not recorded

Safety Considerations

Drug Interactions: 100 interactions were found in the interaction database; examples of major-level interactions include acetylsalicylic acid, ibuprofen, ketorolac, alteplase, abciximab, acalabrutinib, deferasirox and trastuzumab emtansine (mostly additive bleeding risk with antiplatelet, NSAID, thrombolytic or other agents affecting haemostasis). Moderate-level examples include sibutramine, fenfluramine, sugammadex and aliskiren.

Please refer to the package insert for warnings and contraindications, which are not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link to severe protein C deficiency is plausible, but no trial or publication directly studies this disease, so the evidence level is L5 and the prediction remains a research question.

To proceed, the following is needed:

A systematic literature search for enoxaparin or low-molecular-weight heparin use in severe congenital protein C deficiency (case reports, registries)
Health Canada product monograph warnings and contraindications, and approved indication text
Confirmed mechanism-of-action data from a primary source
Specialist haematology input on dosing, monitoring and bleeding risk in neonates and affected patients, including comparison with protein C concentrate and other standard therapies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.